Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Enhanced Stimulation of Antigen-Specific Immune Responses Against NPM1-Mutated AML

Jochen Marlies Greiner, Vanessa Schneider, Hubert Schrezenmeier, Susanne Hofmann, Marlies Götz

Blood (2021) 138 (Supplement 1): 1292.

https://doi.org/10.1182/blood-2021-146875

Published: 2021

Journal Articles

Frequency and Stimulation of NPM1-Specific Immune Responses By Anti-PD1 Antibodies in NPM1-Mutated AML

Jochen Greiner, MD, Vanessa Schneider, Dr. rer. nat., Hubert Schrezenmeier, Markus Wiesneth, MD, Susanne Hofmann, MD, Marlies Götz

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-134876

Published: 2020

Journal Articles

Expression of PD-L1 in Leukemic Progenitor Cells Defines NPM1 Mutated AML As a Potential Subgroup for PD1/PD-L1 Directed Immunotherapy

Jochen Greiner, Vanessa Schneider, Dr. rer. nat., Hubert Schrezenmeier, MD, Markus Wiesneth, MD, Lars Bullinger, MD, Hartmut Döhner, MD, Susanne Hofmann, MD, Marlies Götz

Blood (2018) 132 (Supplement 1): 2734.

https://doi.org/10.1182/blood-2018-99-111458

Published: 2018

Journal Articles

Specific Immune Responses for Leukemia-Associated Antigens Against Myeloid Leukemic Cells Are Increased By Immune Checkpoint Inhibition

Jochen Greiner, Marlies Götz, Vanessa Schneider, Hubert Schrezenmeier, Markus Wiesneth, Lars Bullinger, Hartmut Döhner, MD, Susanne Hofmann

Blood (2016) 128 (22): 4054.

https://doi.org/10.1182/blood.V128.22.4054.4054

Published: 2016

Journal Articles

Cytotoxic T-Cell Responses (CTL) Against Several Leukemia-Associated-Antigens (LAA) Related to the Detected Cytokine Profile in the Course of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Donor Lymphocyte Infusion (DLI) in Patients with Different Hematological Diseases

Susanne Hofmann, MD, Marlies Götz, Cornelia Herbst, Vanessa Schneider, Markus Wiesneth, MD, Donald Bunjes, MD, Hartmut Döhner, MD, Jochen Greiner, MD

Blood (2014) 124 (21): 2442.

https://doi.org/10.1182/blood.V124.21.2442.2442

Published: 2014

Journal Articles

Cytotoxic T-Lymphocytes Recognize and Target Leukemic Stem Cells

Vanessa Schneider, Lu Zhang, Markus Rojewski, Lars Bullinger, MD PhD, Susanne Hofmann, MD, Marlies Goetz, Konstanze Doehner, MD, Hartmut Doehner, Prof., Christian Buske, MD, Jochen Greiner, MD

Blood (2014) 124 (21): 5783.

https://doi.org/10.1182/blood.V124.21.5783.5783

Published: 2014

Journal Articles

Analysis Of Leukemic Stem Cell Population Comparing NPM1 wt and NPM1 mut AML Patients and Potential Therapeutic Targets

Vanessa Schneider, Lars Bullinger, MD, PhD, Lu Zhang, Markus Rojewski, Markus Wiesneth, Susanne Hofmann, Marlies Goetz, Hubert Schrezenmeier, MD, Ulla Botzenhardt, Thomas F.E. Barth, Konstanze Doehner, MD, Hartmut Doehner, MD, Jochen Greiner, MD

Blood (2013) 122 (21): 2624.

https://doi.org/10.1182/blood.V122.21.2624.2624

Published: 2013

Journal Articles

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations ( NPM1 mut )

Jochen Greiner, Vanessa Schneider, Michael Schmitt, Marlies Götz, Konstanze Döhner, Markus Wiesneth, Hartmut Döhner, Susanne Hofmann

Blood (2013) 122 (6): 1087–1088.

https://doi.org/10.1182/blood-2013-04-496844

Published: 2013

Journal Articles

Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1 mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs)

Susanne Hofmann, Vanessa Schneider, Lars Bullinger, Yoko Ono, Anita Schmitt, Lu Zhang, Marlies Götz, Konstanze Döhner, MD, Ph.D, Joannis Mytilineos, Markus Wiesneth, Hartmut Döhner, MD, Michael Schmitt, Jochen Greiner, MD

Blood (2012) 120 (21): 3592.

https://doi.org/10.1182/blood.V120.21.3592.3592

Published: 2012

Journal Articles

The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses

Jochen Greiner, MD, Yoko Ono, Susanne Hofmann, Vanessa Schneider, Anita Schmitt, Lu Zhang, Elmar Mehring, Marlies Götz, Konstanze Döhner, Joannis Mytilineos, Markus Wiesneth, Hartmut Döhner, MD, Michael Schmitt, MD, PhD

Blood (2011) 118 (21): 2569.

https://doi.org/10.1182/blood.V118.21.2569.2569

Published: 2011

Journal Articles

Preemptive Donor Lymphocyte Infusion Induces Polyspecific T-Cell Responses in a Patient with AML with NPM1 Mutation

Susanne Hofmann, Marlies Götz, Cornelia Herbst, Vanessa Schneider, Lu Zhang, Donald Bunjes, MD, Hartmut Döhner, MD, Markus Wiesneth, Jochen Greiner, MD

Blood (2011) 118 (21): 4311.

https://doi.org/10.1182/blood.V118.21.4311.4311

Published: 2011

Journal Articles

Efficiency of Leukemic Stem Cell Separation From Patients with Acute Myeloid Leukemia

Lu Zhang, Susanne Hofmann, Lars Bullinger, Marlies Goetz, Markus Wiesneth, Markus Rojewski, Hartmut Dohner, MD, Jochen Greiner, MD, Vanessa Schneider

Blood (2011) 118 (21): 4997.

https://doi.org/10.1182/blood.V118.21.4997.4997

Published: 2011

NARROW

Enhanced Stimulation of Antigen-Specific Immune Responses Against NPM1-Mutated AML

Frequency and Stimulation of NPM1-Specific Immune Responses By Anti-PD1 Antibodies in NPM1-Mutated AML

Expression of PD-L1 in Leukemic Progenitor Cells Defines NPM1 Mutated AML As a Potential Subgroup for PD1/PD-L1 Directed Immunotherapy

Specific Immune Responses for Leukemia-Associated Antigens Against Myeloid Leukemic Cells Are Increased By Immune Checkpoint Inhibition

Cytotoxic T-Cell Responses (CTL) Against Several Leukemia-Associated-Antigens (LAA) Related to the Detected Cytokine Profile in the Course of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Donor Lymphocyte Infusion (DLI) in Patients with Different Hematological Diseases

Cytotoxic T-Lymphocytes Recognize and Target Leukemic Stem Cells

Analysis Of Leukemic Stem Cell Population Comparing NPM1 wt and NPM1 mut AML Patients and Potential Therapeutic Targets

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations ( NPM1 mut )

Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1 mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs)

The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses

Preemptive Donor Lymphocyte Infusion Induces Polyspecific T-Cell Responses in a Patient with AML with NPM1 Mutation

Efficiency of Leukemic Stem Cell Separation From Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only